This is in line with the well-known immunogenic nature of melanoma and the recent literature pointing at MHC-I/II protein expression as a powerful prognostic marker to predict the effectiveness of anti-CTLA-4 and anti-PD-1 immunotherapy in metastatic melanoma and other cancer types [24,25,26,27,28]. This evidence concerns the gene CTLA4 and melanoma.